206 related articles for article (PubMed ID: 23223314)
1. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Carroll RP; Hester J; Wood KJ; Harden PN
Nephrol Dial Transplant; 2013 Feb; 28(2):462-5. PubMed ID: 23223314
[TBL] [Abstract][Full Text] [Related]
2. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
[TBL] [Abstract][Full Text] [Related]
3. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
Front Immunol; 2021; 12():663602. PubMed ID: 34539621
[TBL] [Abstract][Full Text] [Related]
4. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
[TBL] [Abstract][Full Text] [Related]
5. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.
van den Akker JM; Wetzels JF; Hoitsma AJ
Kidney Int; 2006 Oct; 70(7):1355-7. PubMed ID: 16912706
[TBL] [Abstract][Full Text] [Related]
6. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
7. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
8. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients.
Akimova T; Kamath BM; Goebel JW; Meyers KE; Rand EB; Hawkins A; Levine MH; Bucuvalas JC; Hancock WW
Am J Transplant; 2012 Dec; 12(12):3449-61. PubMed ID: 22994804
[TBL] [Abstract][Full Text] [Related]
9. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.
Kim KW; Chung BH; Kim BM; Cho ML; Yang CW
Immunology; 2015 Jan; 144(1):68-78. PubMed ID: 24974886
[TBL] [Abstract][Full Text] [Related]
10. Timing of mTORI usage and outcomes in kidney transplant recipients.
Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
[TBL] [Abstract][Full Text] [Related]
11. The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19.
Requião-Moura LR; Modelli de Andrade LG; de Sandes-Freitas TV; Cristelli MP; Viana LA; Nakamura MR; Garcia VD; Manfro RC; Simão DR; Almeida RAMB; Ferreira GF; Costa KMAH; de Lima PR; Pacheco-Silva A; Charpiot IMMF; Deboni LM; Ferreira TCA; Mazzali M; Calazans CAC; Oriá RB; Tedesco-Silva H; Medina-Pestana J;
Transplantation; 2022 Oct; 106(10):e441-e451. PubMed ID: 35765133
[TBL] [Abstract][Full Text] [Related]
12. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
[TBL] [Abstract][Full Text] [Related]
13. Immune phenotype of peripheral blood cells and skin squamous cell carcinoma in organ transplant recipients.
Dziunycz P; Hofbauer GF
Expert Rev Clin Immunol; 2010 May; 6(3):359-62. PubMed ID: 20441422
[TBL] [Abstract][Full Text] [Related]
14. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
Lim WH; Eris J; Kanellis J; Pussell B; Wiid Z; Witcombe D; Russ GR
Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
[TBL] [Abstract][Full Text] [Related]
16. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
17. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer.
Peraldi MN; Berrou J; Venot M; Chardiny V; Durrbach A; Vieillard V; Debré P; Charron D; Suberbielle C; Chevret S; Glotz D; Dulphy N; Toubert A
Transplantation; 2015 Nov; 99(11):2422-30. PubMed ID: 26798861
[TBL] [Abstract][Full Text] [Related]
19. Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study.
Fázio MR; Cristelli MP; Tomimori J; Koga CE; Ogawa MM; Beneventi GT; Tedesco-Silva H; Medina-Pestana J
J Bras Nefrol; 2023; 45(4):480-487. PubMed ID: 37565728
[TBL] [Abstract][Full Text] [Related]
20. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
